[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review

September 2021 | 51 pages | ID: I0DB73E697BEN
GlobalData

US$ 125.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

ImmuPharma Plc (ImmuPharma) biopharmaceutical company that focuses on discovery and development of peptide-based therapeutics for the treatment of serious medical conditions with unmet medical need. ImmuPharma develops drugs for the treatment of lupus, cancer, highly resistant hospital-acquired infections such as methicillin-resistant staphylococcus aureus infection. The company’s product pipeline comprises Lupuzor, for the treatment of Lupus; IIP
  • 203101, for treatment of methicillin-resistant Staphylococcus aureus; BioGlucagon for treatment of diabetes and IPP-204106, for the treatment of cancer; and peptide platform for the treatment of metabolic disorders. It has operations in France and Switzerland. ImmuPharma is headquartered in London, Greater London, the UK.

    Immupharma Plc Key Recent Developments

    Jul 30,2021: ImmuPharma: Board changes
    Jul 16,2021: ImmuPharma: Board Appointment
    May 24,2021: Immupharma: Director retirement
    Apr 29,2021: Immupharma announce Final Results
    Apr 29,2021: ImmuPharma: Final results

    Key benefits of buying this profile include:

    You get detailed information about the company and its operations to identify potential customers and suppliers.
    • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
    Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
    • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
    Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
    • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
    Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
    • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
    Gain key insights into the company for academic or business research.
    • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
    Note: Some sections may be missing if data is unavailable for the company
  • SECTION 1 - ABOUT THE COMPANY

    Immupharma Plc - Key Facts
    Immupharma Plc - Key Employees
    Immupharma Plc - Key Employee Biographies
    Immupharma Plc - Major Products and Services
    Immupharma Plc - History
    Immupharma Plc - Company Statement
    Immupharma Plc - Locations And Subsidiaries
    Head Office
    Other Locations & Subsidiaries

    SECTION 2 – COMPANY ANALYSIS

    Company Overview
    Immupharma Plc - Business Description
    Immupharma Plc - Corporate Strategy
    Immupharma Plc - SWOT Analysis
    SWOT Analysis - Overview
    Immupharma Plc - Strengths
    Immupharma Plc - Weaknesses
    Immupharma Plc - Opportunities
    Immupharma Plc - Threats
    Immupharma Plc - Key Competitors

    SECTION 3 – COMPANY FINANCIAL RATIOS

    Financial Ratios - Capital Market Ratios
    Financial Ratios - Annual Ratios
    Performance Chart
    Financial Performance
    Financial Ratios - Interim Ratios
    Financial Ratios - Ratio Charts

    SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

    Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
    Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
    Immupharma Plc, Recent Deals Summary

    SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

    Jul 30, 2021: ImmuPharma: Board changes
    Jul 16, 2021: ImmuPharma: Board Appointment
    May 24, 2021: Imm harma: Director retirement
    Apr 29, 2021: ImmuPharma: Final results
    Apr 29, 2021: Imm harma announce Final Results
    Sep 30, 2020: ImmuPharma : Interim results announcement for the six months ended 30 June 2020
    Apr 30, 2020: ImmuPharma : Final results announcement for the twelve months ended 31 December 2019

    SECTION 6 – APPENDIX

    Methodology
    Ratio Definitions
    About GlobalData
    Contact Us
    Disclaimer

    LIST OF TABLES

    Immupharma Plc, Key Facts
    Immupharma Plc, Key Employees
    Immupharma Plc, Key Employee Biographies
    Immupharma Plc, Major Products and Services
    Immupharma Plc, History
    Immupharma Plc, Subsidiaries
    Immupharma Plc, Key Competitors
    Immupharma Plc, Ratios based on current share price
    Immupharma Plc, Annual Ratios
    Immupharma Plc, Annual Ratios (Cont...1)
    Immupharma Plc, Interim Ratios
    Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
    Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
    Immupharma Plc, Recent Deals Summary
    Currency Codes
    Capital Market Ratios
    Equity Ratios
    Profitability Ratios
    Cost Ratios
    Liquidity Ratios
    Leverage Ratios
    Efficiency Ratios

    LIST OF FIGURES

    Immupharma Plc, Performance Chart (2016 - 2020)
    Immupharma Plc, Ratio Charts
    Immupharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
    Immupharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021


    More Publications